Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
By A. Coates, Eric P. Winer, A. Goldhirsch, R. Gelber, M. Gnant, M. Piccart-Gebhart, B. Thürlimann, H. Senn. Annals of Oncology, 2015
1,760 citations recorded by the source corpus.
The 14th St Gallen International Breast Cancer Conference (2015) reviewed new evidence on locoregional and systemic therapies for early breast cancer. This manuscript presents news and progress since the 2013 meeting, provides expert opinion on almost 200 questions posed to Consensus Panel members, and summarizes treatment-oriented classification of subgroups and treatment recommendations.
Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/6de91c6afb14d63027ae7a4bb1c62c6a0bcc858c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Oncology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Artificial intelligence as the next step towards precision pathology (2020, background): “Although there is controversy about how image analysis should be implemented in the clinical setting [19], computer-based image analysis is bound to increase reproducibility.”
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015, methodology): “A IB evidence level has been achieved from retrospective analyses of data from prospective trials regarding the prognostic value of MammaPrint, Oncotype DX, Prosigna and Endopredict, in ER-positive breast cancers [31, 32].”
- High resolution mapping of the tumor microenvironment using integrated single-cell, spatial and in situ analysis (2023, neutral): “These classi fi cations typically de fi ne treatment strategies; for example, endocrine therapies are commonly used to treat patients with ER+ breast cancers 17 .”
- Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer (2021, background): “Well-known genes previously linked to chemotherapy response including TOP2A [32], MKI67 [33], ABC efflux pumps [34], or APOBEC3B [35] were related to survival following chemotherapy in ER positive tumors only, and none of these genes reached significance in basal tumors.”